+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-1 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
IL-1 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
Sale

IL-1 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6135097
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IL-1 Receptor Antagonist Market is projected to reach USD 2.21 Billion in 2026. It is expected to continue growing at a CAGR of 9.34%, reaching USD 3.78 Billion by 2032.

IL-1 Receptor Antagonists: Executive Overview

IL-1 receptor antagonists are therapeutic agents designed to inhibit signaling driven by interleukin-1, a cytokine associated with inflammation, immune activation, and tissue damage. Their clinical relevance spans autoinflammatory, rheumatic, dermatologic, metabolic, and other inflammatory conditions. Development and adoption are shaped by evidence of disease-modifying activity, treatment safety, administration requirements, reimbursement, and diagnostic clarity.

Clinical Precision and Access Are Reshaping the Field

The landscape is shifting toward more selective patient identification, earlier intervention, and treatment strategies that connect inflammatory biology with measurable clinical outcomes. Regulators, clinicians, and payers are placing greater emphasis on comparative evidence, long-term safety, infection-risk management, and practical treatment pathways. Competition among biologic and targeted anti-inflammatory approaches also increases the importance of differentiation through dosing convenience, route of administration, pediatric usability, and evidence across comorbid populations.

Artificial Intelligence Strengthens Discovery, Trial Design, and Care

Artificial intelligence can support IL-1 antagonist research by identifying inflammatory biomarkers, analyzing genomic and transcriptomic data, and improving patient stratification. In clinical development, machine-learning tools may help locate eligible participants, detect safety signals, optimize trial recruitment, and identify response patterns across heterogeneous diseases. In care delivery, decision-support systems can assist with treatment selection and monitoring, although validation, data quality, transparency, privacy, and clinician oversight remain essential before algorithmic outputs influence therapy.

Regional Insights: Uneven Access and Differing Clinical Priorities

North America combines advanced specialty care and strong clinical research capacity with close scrutiny of safety, reimbursement, and treatment value. Europe emphasizes evidence-based prescribing, health-technology assessment, and coordinated regulatory standards, while access can vary across national systems. Asia-Pacific presents diverse needs, ranging from highly developed biopharmaceutical ecosystems to expanding specialist infrastructure. Latin America is influenced by public procurement, affordability, diagnostic capacity, and uneven specialist access. The Middle East is strengthening tertiary and precision-care capabilities, with adoption shaped by centralized purchasing and imported-medicine access. Africa continues to face constraints involving diagnosis, specialist availability, cold-chain logistics, and financing, making scalable delivery models particularly important.

Group Insights: Policy Alignment and Trade Connectivity Matter

ASEAN countries are likely to require flexible access strategies that reflect substantial differences in health-system maturity, regulatory processes, and public-sector purchasing. BRICS members combine large and diverse patient populations with growing interest in domestic manufacturing, local clinical evidence, and broader biologic access. The European Union benefits from shared regulatory structures but retains national differences in reimbursement and service delivery. G7 health systems generally support sophisticated research, pharmacovigilance, and specialist treatment pathways, while demanding robust evidence. GCC countries often have concentrated tertiary-care networks and centralized procurement, and NATO members may benefit from resilient research and supply-chain cooperation, although civilian access remains governed by national health policies.

Country Insights: National Systems Shape Adoption Pathways

Australia and Canada emphasize specialist-led access, public reimbursement evaluation, and geographically responsive care. Brazil and Mexico face the combined priorities of affordability, public-sector procurement, and expansion of specialist diagnosis. China and India are balancing growing biomedical capability with regulatory localization, manufacturing development, and broad access across diverse populations. Japan and South Korea have advanced clinical infrastructure and strong regulatory expectations, with attention to safety, post-market monitoring, and treatment practicality. France, Germany, Italy, Spain, and the United Kingdom differ in assessment, procurement, and reimbursement mechanisms despite extensive specialist capacity. Russia’s pathway is influenced by domestic supply considerations, regulatory conditions, and healthcare-system constraints. The United States remains highly focused on specialist prescribing, evidence generation, payer coverage, and safety monitoring.

Actions for Leaders: Build Evidence, Access, and Resilience Together

Industry leaders should prioritize well-defined patient populations, clinically meaningful endpoints, and evidence that clarifies positioning against established anti-inflammatory options. Companion diagnostic work, real-world evidence, and transparent safety monitoring can improve confidence among clinicians and payers. Access planning should address cold-chain requirements, administration settings, pediatric use, and public procurement from the outset. Regional operating models should be tailored to local regulatory and reimbursement conditions rather than replicated uniformly. Organizations should also establish responsible AI governance, diversify critical supply inputs, strengthen pharmacovigilance, and collaborate with clinicians and patient groups on treatment education.

Methodology: Evidence-Led Market Landscape Assessment

This executive summary uses a structured qualitative assessment of IL-1 receptor antagonist development and use. The analysis considers therapeutic biology, clinical evidence needs, regulatory and reimbursement factors, healthcare delivery conditions, regional and country-level system characteristics, supply-chain considerations, and the potential role of artificial intelligence. Insights are framed without market estimates, market shares, forecasts, company references, or unsupported numerical claims. Country and group observations are interpreted as contextual patterns rather than measurements of commercial performance.

Conclusion: Success Depends on Precision, Proof, and Practical Delivery

IL-1 receptor antagonists occupy an important position in targeted inflammation management, but their impact depends on more than pharmacology alone. Strong patient selection, credible comparative evidence, responsible safety management, and workable delivery models will determine clinical value across diverse health systems. Leaders that connect scientific precision with equitable access, resilient operations, and disciplined digital innovation will be best positioned to support durable adoption.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IL-1 Receptor Antagonist Market, by Indication
7.1. Introduction
7.2. Cryopyrin-Associated Periodic Syndromes
7.3. Gout
7.4. Rheumatoid Arthritis
8. IL-1 Receptor Antagonist Market, by Route Of Administration
8.1. Introduction
8.2. Intraperitoneal
8.3. Intravenous
8.3.1. Infusion Bag
8.3.2. Vial
8.4. Subcutaneous
8.4.1. Pre-Filled Pen
8.4.2. Prefilled Syringe
8.4.2.1. Multi-Dose
8.4.2.2. Single-Dose
9. IL-1 Receptor Antagonist Market, by Dosage Form
9.1. Introduction
9.2. Auto-Injector
9.3. Liquid
9.4. Powder
9.5. Prefilled Syringe
9.5.1. Multi-Dose
9.5.2. Single-Dose
10. IL-1 Receptor Antagonist Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. IL-1 Receptor Antagonist Market, by End-User
11.1. Introduction
11.2. Home Healthcare
11.3. Hospital
11.4. Specialty Clinic
12. IL-1 Receptor Antagonist Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
12.5. Specialty Pharmacy
13. IL-1 Receptor Antagonist Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. IL-1 Receptor Antagonist Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. IL-1 Receptor Antagonist Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. AstraZeneca PLC
17.4. Bristol-Myers Squibb Company
17.5. Cytos Biotechnology AG
17.6. Eli Lilly and Company
17.7. GlaxoSmithKline plc
17.8. Janssen Biotech, Inc.
17.9. Kiniksa Pharmaceuticals, Ltd.
17.10. Merck & Co., Inc.
17.11. Novartis AG
17.12. Olatec Therapeutics, Inc.
17.13. Protagonist Therapeutics, Inc.
17.14. Regeneron Pharmaceuticals, Inc.
17.15. Roche Holding AG
17.16. Sanofi
17.17. Swedish Orphan Biovitrum AB
17.18. Vertex Pharmaceuticals Incorporated
17.19. XBiotech Inc.
17.20. XOMA Corporation
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global IL-1 Receptor Antagonist Market, Years Considered for the Study
FIGURE 2. Global IL-1 Receptor Antagonist Market, Research Design
FIGURE 3. Global IL-1 Receptor Antagonist Market, Research Framework
FIGURE 4. Global IL-1 Receptor Antagonist Market, Data Triangulation
FIGURE 5. Global IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
FIGURE 6. Global IL-1 Receptor Antagonist Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global IL-1 Receptor Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 13. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global IL-1 Receptor Antagonist Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 15. Global IL-1 Receptor Antagonist Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global IL-1 Receptor Antagonist Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global IL-1 Receptor Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global IL-1 Receptor Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global IL-1 Receptor Antagonist Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global IL-1 Receptor Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global IL-1 Receptor Antagonist Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global IL-1 Receptor Antagonist Market Segmentation & Coverage
TABLE 2. Global IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 3. Global IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cryopyrin-Associated Periodic Syndromes Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gout Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 14. Global Intraperitoneal Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Intraperitoneal Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Intraperitoneal Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Infusion Bag Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Infusion Bag Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Infusion Bag Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Pre-Filled Pen Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Pre-Filled Pen Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Pre-Filled Pen Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Multi-Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Multi-Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Multi-Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Single-Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Single-Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Single-Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 42. Global Auto-Injector Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Auto-Injector Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Auto-Injector Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Multi-Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Multi-Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Multi-Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Single-Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Single-Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Single-Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 61. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 68. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. North America IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. North America IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. North America IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. North America IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 106. North America IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 107. North America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 108. North America IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 109. North America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 110. North America IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 111. North America IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 112. North America IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Latin America IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Latin America IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. Latin America IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. Latin America IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 117. Latin America IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 118. Latin America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 119. Latin America IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 120. Latin America IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 121. Latin America IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 122. Latin America IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 123. Latin America IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Europe IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Europe IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 126. Europe IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. Europe IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 128. Europe IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 129. Europe IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 130. Europe IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 131. Europe IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 132. Europe IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 133. Europe IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 134. Europe IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. Middle East IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Middle East IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. Middle East IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. Middle East IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 139. Middle East IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 140. Middle East IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 141. Middle East IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 142. Middle East IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 143. Middle East IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 144. Middle East IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 145. Middle East IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Africa IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Africa IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. Africa IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. Africa IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 150. Africa IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 151. Africa IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 152. Africa IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 153. Africa IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 154. Africa IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 155. Africa IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 156. Africa IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Global IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. ASEAN IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. ASEAN IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. ASEAN IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. ASEAN IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 162. ASEAN IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 163. ASEAN IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 164. ASEAN IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 165. ASEAN IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 166. ASEAN IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 167. ASEAN IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 168. ASEAN IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. GCC IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. GCC IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. GCC IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 172. GCC IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 173. GCC IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 174. GCC IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 175. GCC IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 176. GCC IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 177. GCC IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 178. GCC IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 179. GCC IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. European Union IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. European Union IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 182. European Union IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. European Union IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 184. European Union IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 185. European Union IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 186. European Union IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. European Union IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 188. European Union IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 189. European Union IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 190. European Union IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. BRICS IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 192. BRICS IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. BRICS IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. BRICS IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 195. BRICS IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 196. BRICS IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 197. BRICS IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 198. BRICS IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 199. BRICS IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 200. BRICS IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 201. BRICS IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. G7 IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. G7 IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. G7 IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 205. G7 IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 206. G7 IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 207. G7 IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 208. G7 IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 209. G7 IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 210. G7 IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 211. G7 IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 212. G7 IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. NATO IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. NATO IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. NATO IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. NATO IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 217. NATO IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 218. NATO IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 219. NATO IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 220. NATO IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 221. NATO IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 222. NATO IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 223. NATO IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. Global IL-1 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 225. United States IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 226. United States IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. United States IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 228. United States IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 229. United States IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 230. United States IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 231. United States IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 232. United States IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 233. United States IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 234. United States IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 235. United States IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Canada IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 237. Canada IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. Canada IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. Canada IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 240. Canada IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 241. Canada IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 242. Canada IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 243. Canada IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 244. Canada IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 245. Canada IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 246. Canada IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. Mexico IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 248. Mexico IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 249. Mexico IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 250. Mexico IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 251. Mexico IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 252. Mexico IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 253. Mexico IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 254. Mexico IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 255. Mexico IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 256. Mexico IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 257. Mexico IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. Brazil IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 259. Brazil IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. Brazil IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 261. Brazil IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 262. Brazil IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 263. Brazil IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 264. Brazil IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 265. Brazil IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 266. Brazil IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 267. Brazil IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 268. Brazil IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. United Kingdom IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 270. United Kingdom IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 271. United Kingdom IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. United Kingdom IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 273. United Kingdom IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 274. United Kingdom IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 275. United Kingdom IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 276. United Kingdom IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 277. United Kingdom IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 278. United Kingdom IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 279. United Kingdom IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 280. Germany IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 281. Germany IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 282. Germany IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 283. Germany IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 284. Germany IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 285. Germany IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 286. Germany IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 287. Germany IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 288. Germany IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 289. Germany IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 290. Germany IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. France IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 292. France IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. France IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 294. France IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 295. France IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 296. France IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 297. France IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 298. France IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 299. France IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 300. France IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 301. France IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Russia IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 303. Russia IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 304. Russia IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 305. Russia IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 306. Russia IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 307. Russia IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 308. Russia IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 309. Russia IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 310. Russia IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 311. Russia IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 312. Russia IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. Italy IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 314. Italy IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 315. Italy IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Italy IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 317. Italy IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 318. Italy IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 319. Italy IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 320. Italy IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 321. Italy IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 322. Italy IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 323. Italy IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 324. Spain IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 325. Spain IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 326. Spain IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 327. Spain IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 328. Spain IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 329. Spain IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 330. Spain IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 331. Spain IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 332. Spain IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 333. Spain IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 334. Spain IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. China IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 336. China IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 337. China IL-1 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 338. China IL-1 Receptor Antagonist Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 339. China IL-1 Receptor Antagonist Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 340. China IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 341. China IL-1 Receptor Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 342. China IL-1 Receptor Antagonist Market Size, by Prefilled Syringe, 2017-2032 (USD Million)
TABLE 343. China IL-1 Receptor Antagonist Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 344. China IL-1 Receptor Antagonist Market Size, by End-User, 2017-2032 (USD Million)
TABLE 345. China IL-1 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 346. India IL-1 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 347. India IL-1 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 348. India IL-1 Receptor Antagonist Market Size, by

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cytos Biotechnology AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics, Inc.
  • Protagonist Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • Vertex Pharmaceuticals Incorporated
  • XBiotech Inc.
  • XOMA Corporation

Related Topics

Related Reports

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
IL-23 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-23 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors - Product Image

Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors

  • Report
  • Global
From
Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Monoclonal Antibodies - Competitive Landscape, 2026 - Product Image

Monoclonal Antibodies - Competitive Landscape, 2026

  • Report
  • 450 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.